Bio-Techne and Nucleai Develop AI Spatial Biology Workflow for Predictive Biomarker Discovery

Bio-Techne, a global provider of life science tools and diagnostic products along with Nucleai, have announced an AI-powered spatial biology workflow designed to accelerate predictive biomarker discovery in melanoma research. The integrated solution uses AI and biotechnology for effective treatment options personalized to the patient's needs. Early results indicate improved accuracy in identifying biomarkers linked to patient response to immunotherapy.

The partnership highlights AI’s expanding role in oncology diagnostics. By combining imaging chemistry with machine learning, Bio-Techne and Nucleai aim to enable translational researchers to move from static tissue profiling to predictive, patient-specific biomarker discovery.

Posted by MedCloudInsider Editors on 11/04/2025